Agra Ventures Ltd. (CSE:AGRA, OTC:AGFAF) has revealed that its wholly-owned subsidiary Farmako GmbH has expanded its portfolio of cannabis identity testing kits to now offer a model that tests for both tetrahydrocannabinol (THC) and cannabidiol (CBD).
The Vancouver, British-Columbia-based diversified cannabis company said the New Testkit is validated for a broad range of cannabis products, which differentiates it from other tests. It facilitates the identity testing of different types of cannabis medicines and active pharmaceutical ingredients, noted the company.
“It is also cheaper than obtaining test results through thin layer chromatography,” added the company.
READ: Agra Ventures receives test results for four successful cannabis batches from its Delta greenhouse
Agra Ventures said pharmacies in Germany can now order the New Testkit from Farmako which meets pharmacy regulations. The company explained that while waiting for the result of the THC test, which works with a test strip and a ready-to-use test solution, the CBD test can be conducted through a color test in a second ready-to-use test solution.
“This sequence saves pharmacists valuable time and each New Testkit also contains a test protocol that can be used by pharmacists for documentation purposes,” said the company.
The company said the specificity of the New Testkit has been validated by an independent lab for THC-dominant, CBD-dominant, THC/CBD balanced flowers, different cannabis extracts, Dronabinol and CBD isolate. The validation process makes Farmako’s New Testkit the broadest applicable testkit in the German market, noted the company.
“We are proud to launch the New Testkits and are very happy with the early positive feedback from the market. Our biggest goal is to reduce hurdles for cannabis patients, manufacturers, medical and pharmaceutical staff,” Farmako Managing Director Katrin Eckmans said in a statement.
“In order advance cannabis therapy, it is so important to make the work of doctors and pharmacists easier. Therefore, the possibility of conducting identity testing via validated quick-tests is a very important step in making cannabinoid therapy less complicated. We are proud to be one of the driving forces in this movement,” she added.
New Testkit complements Farmako’s proprietary THC Testkit, which has been on the market since December of 2020. Additionally, Farmako is launching a CBD-only testkit to complete the portfolio.
“The innovation demonstrated by Katrin and her team at Farmako through the creation and launch of the New Testkit is a great achievement. I am pleased with Farmako’s maturation as a subsidiary of Agra Ventures and applaud the efforts of its staff to add value to the overall organization,” said Agra Ventures CEO and Director Elise Coppens. “The strategic evolution of Agra Ventures continues to be positive, based on the progress being made in Germany and the growth occurring at Boundary Bay Cannabis in British Columbia.”
Agra Ventures’ brands and subsidiaries offer a portfolio of cannabis and related products to customers on a multinational basis. It is leveraging advanced technology, innovative practices, and one of the largest greenhouse complexes in the world to develop, produce and distribute high-potency and affordable cannabis products.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive